Dipyridamole in the nephritides

American Journal of Therapeutics

Volumn 5, Issue 2, 1998, Pages 107-109

  Wardle, E Nigel ^a  

^a NONE   (United Kingdom)

Author keywords

Adenosine; Antioxidant action; Antiplatelet therapy; Dipyridamole; Glomerulonephritis; IgA nephropathy

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; COLLAGEN; CYCLIC AMP; CYCLIC GMP PHOSPHODIESTERASE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; METHYLPREDNISOLONE; NITRIC OXIDE; OXYGEN RADICAL; PHOSPHODIESTERASE; PREDNISOLONE; PROSTACYCLIN; RENIN; SUPEROXIDE;

ANAPHYLACTOID PURPURA; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; FOCAL GLOMERULONEPHRITIS; GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LIPID PEROXIDATION; MACROPHAGE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0031924695     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199803000-00009     Document Type: Review

References (36)

1. Schafter AI: Antiplatelet therapy. Am J Med 1996;101: 199-209.
2. Klimt CR, Knotterud GL, Stamler J, Meier P: Persantine-aspirin reinfarction study. II. Secondary prevention with Persantine and aspirin. J Am Coll Cardiol 1986;7:251-259.
3. Fitzgerald GA: Dipyridamole. N Engl J Med 1987;316: 1247-1257.
4. Rajoh SM, Nair U, Rees M, et al: Effect of anti-platelet therapy with indobufen or aspirin-dipyridamole on graft patency 1 year after coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;107:1146-1153.
5. Hess H, Mietasch K, Deichel G: Drug induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double-blind angiographically controlled trial. Lancet 1985;i:415-419.
6. Bousser MG, Eschwege E, Haguenau M: AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic ischemia. Stroke 1983;14:5-14.
7. Selley ML, Czeti AL, McGuiness JA, et al: Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis 1994;111:91-97.
8. Iuliano L, Pedersen JZ, Rotilo G, et al: A potent chain-breaking antioxidant activity of the cerebrovascular drug dipyridamole. Free Radical Biol Med 1995;18:239-247.
9. Bozzo J, Hernandez MR, Ordinas A: Reduced red cell deformability associated with blood flow and platelet activation improved by dipyridamole alone or combined with aspirin. Cardiovasc Res 1995;30:725-730.
10. Wardle EN: Pharmacological mediators and the immunopathology of nephritis. In: Glomerulopathies: Cell Biology and Immunology. Academic Press, Harwood, The Netherlands, 1996, pp 77-110.
11. Yoshimura A, Ideura T, Sato M, et al: The effect of PAF on BSA nephritis in rabbits. In 10th International Congress of Nephrology. Ballière Tindall, Philadelphia, 1987, p 369.
12. Garcia J, Potterman C, Bahler C, et al: Thrombin receptor activating peptides induce calcium mobilisation, barrier dysfunction, prostaglandin synthesis and PDGF mRNA expression in cultured endothelium. J Cell Physiol 1993; 156:541-548.
13. Weyrich AS, Elstad MR, McEver RP, et al: Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996;97:1525-1534.
14. Ward PA, Cunningham TW, McCullard KK, et al: Platelet enhancement of superoxide anion responses in stimulated human neutrophils. Lab Invest 1988;58:37-47.
15. 4 cooperative synthesis. Thromb Haemostasis 1994;73:450-455.
16. Shah SV: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 1989;35:1093-1106.
17. De La Cruz JP, Ortega G, Sanchez de la Cuesta F: Differential effects of pyrimido-pyrimidine derivatives dipyridamole and mopidamol on platelet and vascular cyclo-oxygenase activity. Biochem Pharmacol 1994;47:209-215.
18. Kinsella JP, Toriella F, Ziegler JW, et al: Dipyridamole augmentation of response to nitric oxide. Lancet 1995; 346:647-648.
19. Taddeo S, Aczilli F, Arrighi P, et al: Dipyridamole decreases circulating renin-angiotensin system activity in hypertensive patients. Am J Hypertens 1992;5:29-31.
20. De La Cruz P, Garcia PJ, Sanchez de la Cuesta F: Dipyridamole inhibits platelet aggregation induced by oxygen derived free radicals. Thromb Res 1992;66:277-285.
21. Suzuki S, Sugai K, Sato H, et al: Inhibition of active oxygen generation by dipyridamole in human PMN leukocytes. Eur J Pharmacol 1992;227:395-401.
22. Moncada S, Korbut R: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978;i: 1286-1289.
23. Omer A, Tinaztere K, Erdogen O: The effect of triple therapy on a rapidly progressive type of Henoch-Schönlein nephritis. Pediatr Nephrol 1995;9:6-10.
24. Suzuki N, Oiwa Y, Sugano I, et al: Dipyridamole enhances an antiproliferative effect of Interferon in various types of human tumor cells. Int J Cancer 1992;51:627-633.
25. Dearing MP, Englee-Miller MJ, Kratzke RA, et al: Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin against human lung cancer cell lines. J Cell Biochem Suppl 1996;24:165-172.
26. Camara S, de la Cruz JP, Fritos MA, et al: Effects of dipyridamole on the short term evolution of glomerulonephritis. Nephron 1991;58:13-16.
27. Cronstein BN, Levin RN, Belanoff I, et al: Adenosine: an endogenous inhibitor of neutrophil mediated injury to endothelial cells. J Clin Invest 1986;78:760-770.
28. Jong PE, van der Meer J, van der Hem GK: The antiproteinuric effect of dipyridamole is the consequence of efferent vasodilatation. Kidney Int 1986;29:184-188.
29. De La Cruz JP, Camara S, Frutos MA, et al: Effect of dipyridamole with or without aspirin on urinary protein excretion in patients with membranous glomerulonephritis. Eur J Clin Pharmacol 1992;43:307-309.
30. Murphy BF, McDonald I, Fairley KF, et al: Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 1992;37:229-234.
31. Zauner I, Bohler J, Braun N, et al: Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis. Nephrol Dial Transplant 1994;9:619-622.
32. Vallon V, Osswald H: Dipyridamole prevents diabetes induced alteration of kidney function in rats. Naunyn-Schmiedebergs Arch Pharmacol 1994;349:217-222.
33. Tsai T-J, Lin R-H, Chang C-C, et al: Vasodilator agents modulate rat glomerular mesangial cell growth and collagen synthesis. Nephron 1995;70:91-99.
34. Takehara K, Igarashi A, Ishibashi Y: Dipyridamole specifically decreases platelet derived growth factor release from platelets. Thrombos Res 1990;60(suppl XII):73-79.
35. Park CW, Kim YO, Shin YS, et al: Long term benefits of aspirin plus dipyridamole and angiotensin converting enzyme inhibitor therapy in patients with immunoglobulin A nephropathy. Kidney Int [Abstract] 1997;51:969.
36. Sanaka T, Nakano Y, Nishimura H, et al: Therapeutic effect of newly developed antioxidative agent (OPC-15161) on experimental immune complex nephritis. Nephron 1997;76:315-322.